NEW YORK (GenomeWeb News) – Molecular imaging firm Edinburgh Molecular Imaging has received £4 million ($6.5 million) in a Series A investment, life science capital venture fund Epidarex Capital announced today.
Regulus Therapeutics remains on track to filing an investigational new drug application for its microRNA-targeting hepatitis C treatment RG-101 next year, with a second candidate — likely for fibrosis or cancer — to be added to the company's formal pipeline before the end of 2013
The management of Regulus Therapeutics last week provided a few new details on the company's pipeline, promising that it would have two microRNA drug candidates ready for clinical trials before the end of next year.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Epistem today announced a research collaboration with GlaxoSmithKline to use its amplification technology to gain a better understanding of fibrosis.